Pharming Group announces third quarter 2026 revenues above market expectationsGlobeNewsWire · 4 days ago
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026GlobeNewsWire · Oct 14, 2026
Pharming Group: Viable Contrarian Buy If Ruconest StabilizesSeeking Alpha · Sep 30, 2026
Pharming announces CEO transitionGlobeNewsWire · Sep 29, 2026
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSGlobeNewsWire · Sep 25, 2026
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026GlobeNewsWire · Sep 22, 2026Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.06 | $0.02 | Miss |
| May 7, 2026 | $0.05 | -$0.07 | Miss |
| Mar 12, 2026 | $0.02 | $0.07 | Beat |
| Nov 6, 2025 | $0.05 | $0.10 | Beat |
| Jul 31, 2025 | -$0.10 | $0.06 | Beat |
| May 8, 2025 | -$0.03 | -$0.22 | Miss |